Irritable Bowel Syndrome Characterized by Constipation Completed Phase 3 Trials for Plecanatide (DB13170)

IndicationStatusPhase
DBCOND0044250 (Irritable Bowel Syndrome Characterized by Constipation)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02387359The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)Treatment
NCT02493452Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)Treatment